verezdoВестник репродуктивного здоровьяBulletin of Reproductive Health2075-65692310-421XEndocrinology Research Centre (Moscow)10.14341/brh12788verezdo-12800Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESРоссийские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ РКО, РОАГ, РАЭ, ЕАТ, АФР, РНМОТ, РАГГRussian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGGhttps://orcid.org/0000-0003-2929-0980ШляхтоЕ. В.ShlyakhtoE. V.

Шляхто Евгений Владимирович - д.м.н., профессор.

Evgeny V. Shlyakhto - MD, PhD, Professor.

info@scardio.ruhttps://orcid.org/0000-0002-8175-7886ДедовИ. И.DedovI. I.

Дедов Иван Иванович - д.м.н., профессор.

Ivan I. Dedov - MD, PhD, Professor.

info@rae-org.ruhttps://orcid.org/0000-0003-2976-7128СеровВ. Н.SerovV. N.

Серов Владимир Николаевич - д.м.н., профессор.

Vladimir N. Serov - MD, PhD, Professor.

v_serov@oparina4.ruhttps://orcid.org/0000-0002-7712-1260СухихГ. Т.SukhikhG. T.

Сухих Геннадий Тихонович - д.м.н., профессор.

Gennady T. Sukhikh - MD, PhD, Professor.

secretariat@oparina4.ruhttps://orcid.org/0000-0002-6645-2515АрутюновГ. П.ArutyunovG. P.

Арутюнов Григорий Павлович - д.м.н., профессор.

Grigory P. Arutyunov - MD, PhD, Professor.

arut@ossn.ruСучковИ. А.SuchkovI. A.

Сучков Игорь Александрович - д.м.н., профессор.

Igor A. Suchkov - MD, PhD, Professor.

suchkov_med@mail.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Михайловна - член-корреспондент РАН, д.м.н., профессор.

Oksana M. Drapkina - MD, PhD, Professor.

drapkina@bk.ruhttps://orcid.org/0000-0002-4193-688XТкачеваО. Н.TkachevaO. N.

Ткачева Ольга Николаевна - д.м.н., профессор.

Olga N. Tkacheva - MD, PhD, Professor.

tkacheva@rgnkc.ruhttps://orcid.org/0000-0002-8160-5612ОрловаЯ. А.OrlovaYa. A.

Орлова Яна Артуровна - д.м.н.

Yana A. Orlova - MD, PhD.

5163002@bk.ruhttps://orcid.org/0000-0002-9813-2823БарановИ. И.BaranovI. I.

Баранов Игорь Иванович - д.м.н., профессор.

Igor I. Baranov - MD, Dr. Sc. (Med.)

I_baranov@oparina4.ruhttps://orcid.org/0000-0001-8425-0020АндрееваЕ. Н.AndreevaE. N.

Андреева Елена Николаевна - д.м.н., профессор.

Elena N. Andreeva - MD, PhD, Professor.

endogin@mail.ruhttps://orcid.org/0000-0003-2864-066XЮреневаС. В.YurenevaS. V.

Юренева Светлана Владимировна - д.м.н., профессор.

Svetlana V. Yureneva - MD, PhD, Professor.

syureneva@gmail.comhttps://orcid.org/0000-0002-6551-4147ЯрмолинскаяМ. И.YarmolinskayaM. I.

Ярмолинская Мария Игоревна - д.м.н., профессор.

Maria I. Yarmolinskaya - MD, PhD, Professor.

m.yarmolinskaya@gmail.comhttps://orcid.org/0000-0002-0627-3902СметникА. А.SmetnikA. A.

Сметник Антонина Александровна - к.м.н.

Antonina A. Smetnik - MD, PhD.

asmetnik@gmail.comhttps://orcid.org/0000-0001-7652-2962ВиллевальдеС. В.VillevaldeS. V.

Виллевалде Светлана Вадимовна - д.м.н.

Svetlana V. Villevalde - MD, PhD, Professor.

villevaldes@mail.ruhttps://orcid.org/0000-0001-7003-5186КозиоловаН. А.KoziolovaN. A.

Козиолова Наталья Андреевна - д.м.н., профессор.

Natalya A. Koziolova - MD, PhD, Professor.

nakoziolova@mail.ruhttps://orcid.org/0000-0003-1534-3965СергиенкоИ. В.SergienkoI. V.

Сергиенко Игорь Владимирович - д.м.н., профессор.

Igor V. Sergienko MD, PhD, Professor.

igorcardio@mail.ruhttps://orcid.org/0000-0003-2816-1183ЯвеловИ. С.YavelovI. S.

Явелов Игорь Семенович - д.м.н., профессор.

Svetlana V. Villevalde - MD, PhD, Professor.

yavelov@yahoo.comhttps://orcid.org/0000-0002-8656-3191ИртюгаО. Б.IrtyugaO. B.

Иртюга Ольга Борисовна - д.м.н. профессор.

Evgeniy A. Ilyukhin - MD, PhD.

olgir@yandex.ruhttps://orcid.org/0000-0003-4979-7420ГригорянО. Р.GrigoryanO. R.

Григорян Ольга Рафаэльевна -д.м.н., профессор.

117036, Москва, ул. Дм. Ульянова, д. 11

Оlga R. Grigoryan - MD, PhD, Professor.

11 Dm. Ulyanova street, 117036 Moscow

iceberg1995@mail.ruhttps://orcid.org/0000-0001-7891-6850ДудинскаяЕ. Н.DudinskayaE. N.

Дудинская Екатерина Наильевна - д.м.н.

Ekaterina N. Dudinskaya - MD, PhD.

katharina.gin@gmail.comhttps://orcid.org/0000-0002-6563-0471ЗолотухинИ. А.ZolotukhinI. A.

Золотухин Игорь Анатольевич - д.м.н, профессор.

Igor A.Zolotukhin - MD, PhD, Professor.

ИлюхинЕ. А.IlyukhinE. A.

Илюхин Евгений Аркадьевич - к.м.н.

Olga B. Irtyuga.

iluhin-e@yandex.ru202626042026014069Copyright © Шляхто Е.В., Дедов И.И., Серов В.Н., Сухих Г.Т., Арутюнов Г.П., Сучков И.А., Драпкина О.М., Ткачева О.Н., Орлова Я.А., Баранов И.И., Андреева Е.Н., Юренева С.В., Ярмолинская М.И., Сметник А.А., Виллевальде С.В., Козиолова Н.А., Сергиенко И.В., Явелов И.С., Иртюга О.Б., Григорян О.Р., Дудинская Е.Н., Золотухин И.А., Илюхин Е.А., 20262026Шляхто Е.В., Дедов И.И., Серов В.Н., Сухих Г.Т., Арутюнов Г.П., Сучков И.А., Драпкина О.М., Ткачева О.Н., Орлова Я.А., Баранов И.И., Андреева Е.Н., Юренева С.В., Ярмолинская М.И., Сметник А.А., Виллевальде С.В., Козиолова Н.А., Сергиенко И.В., Явелов И.С., Иртюга О.Б., Григорян О.Р., Дудинская Е.Н., Золотухин И.А., Илюхин Е.А.Shlyakhto E.V., Dedov I.I., Serov V.N., Sukhikh G.T., Arutyunov G.P., Suchkov I.A., Drapkina O.M., Tkacheva O.N., Orlova Y.A., Baranov I.I., Andreeva E.N., Yureneva S.V., Yarmolinskaya M.I., Smetnik A.A., Villevalde S.V., Koziolova N.A., Sergienko I.V., Yavelov I.S., Irtyuga O.B., Grigoryan O.R., Dudinskaya E.N., Zolotukhin I.A., Ilyukhin E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vrz-endojournals.ru/jour/article/view/12800

Климактерические симптомы могут нарушать ход жизни женщин на пике карьеры и семейной жизни. В настоящее время самым эффективным методом лечения этих проявлений является менопаузальная гормональная терапия (МГТ).

Наличие сердечно-сосудистых и метаболических заболеваний не исключает возможность назначения МГТ с целью купирования климактерических симптомов и улучшения качества жизни. Однако нередко препятствием для использования этого вида гормональной терапии являются опасения врачей, которые боятся принести пациенткам больше вреда, чем пользы. Осторожность особенно важна, когда речь идет о женщинах, страдающих сопутствующими заболеваниями. Более того, следует признать, что качественных исследований относительно безопасности МГТ при основных хронических неинфекционных заболеваниях и часто встречаемых коморбидных состояниях недостаточно. В представленном согласительном документе проведен анализ всех доступных в настоящее время данных, полученных в ходе клинических исследований различного дизайна, и создан свод критериев приемлемости назначения МГТ женщинам с сопутствующими сердечно-сосудистыми и метаболическими заболеваниями. Опираясь на представленный документ, врачи различных специальностей, консультирующие женщин в климактерии, получат доступный алгоритм, позволяющий избегать потенциально опасных ситуаций и обоснованно назначать МГТ в клинической практике.

Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice

менопаузальная гормональная терапиясердечно-сосудистые заболеванияметаболические заболеваниясахарный диабетвенозные тромбоэмболические осложненияmenopausal hormone therapycardiovascular diseasesmetabolic diseasesdiabetesvenous thromboembolic complicationsРабота выполнена по инициативе авторов без привлечения финансированияReferencesПравительство Российской Федерации. Распоряжение Правительства Российской Федерации от 29.12.2022 № N 4356-p «Об утверждении Национальной стратегии действий в интересах женщин на 2023—2030 годы». Доступно на: https://www.consultant.ru/document/cons_doc_LAW_436691Government of the Russian Federation. Order of the Government of the Russian Federation dated 29.12.2022 No. 4356-p “Approval of the National Strategy for Women’s Action for 2023-2030”. Av. at: https://www.consultant.ru/document/cons_doc_LAW_436691Улумбекова Г.Э., Худова И.Ю. Оценка демографического, социального и экономического эффекта при приеме менопаузальной гормональной терапии. ОРГЗДРАВ: новости, мнения, обучения. // Вестник ВШОУЗ. — 2020. — Т.6. — №4(22). — С.23–53. doi: https://doi.org/10.24411/2411-8621-2020-14002Ulumbekova GE, Khudova IYu. Demographic, social and economic effects of menopause hormonal therapy. Healthcare Management. News, Views, Education. Bulletin of VSHOUZ. 2020;6(4(22)):23–53 (In Russ.) doi: https://doi.org/10.24411/2411-8621-2020-14002Lambrinoudaki I, Armeni E, Goulis D, Bretz S, Ceausu I, Durmusoglu F, et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022;163:1–14. doi: https://doi.org/10.1016/j.maturitas.2022.04.008Lambrinoudaki I, Armeni E, Goulis D, Bretz S, Ceausu I, Durmusoglu F, et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022;163:1–14. doi: https://doi.org/10.1016/j.maturitas.2022.04.008Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2021. Доступно на: https://cr.minzdrav.gov.ru/previewcr/117_2Ministry of Health of the Russian Federation. Clinical Guidelines.Menopause and female climacteric states. 2021. Av. at: https:// cr.minzdrav.gov.ru/preview-cr/117_2Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387–95. doi: https://doi.org/10.1097/gme.0b013e31824d8f40Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387–95. doi: https://doi.org/10.1097/gme.0b013e31824d8f40Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. SpringerPlus. 2015;4(1):65. doi: https://doi.org/10.1186/s40064-015-0808-yDrewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. SpringerPlus. 2015;4(1):65. doi: https://doi.org/10.1186/s40064-015-0808-ySchnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham D, O’Sullivan DM. The North American Menopause Society: from abstract to publication. Menopause. 2008;15(5):996–1001. doi: https://doi.org/10.1097/gme.0b013e318166f026Schnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham D, O’Sullivan DM. The North American Menopause Society: from abstract to publication. Menopause. 2008;15(5):996–1001. doi: https://doi.org/10.1097/gme.0b013e318166f026Paramsothy P, Harlow SD, Nan B, Greendale GA, Santoro N, Crawford SL, et al. Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause. 2017;24(2):142–9. doi: https://doi.org/10.1097/GME.0000000000000736Paramsothy P, Harlow SD, Nan B, Greendale GA, Santoro N, Crawford SL, et al. Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause. 2017;24(2):142–9. doi: https://doi.org/10.1097/GME.0000000000000736Министерство здравоохранения Российской Федерации. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации. 2015. Доступно на: https://www.consultant.ru/document/cons_doc_LAW_320073Ministry of Health of Russian Federation. Menopausal hormone therapy and maintaining the health of women in adulthood. Clinical Guidelines. 2015. Av. at: https://www.consultant.ru/document/cons_doc_LAW_320073Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. International Journal of Epidemiology. 2014;43(5):1542–62. doi: https://doi.org/https://doi.org/10.1093/ije/dyu094Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. International Journal of Epidemiology. 2014;43(5):1542–62. doi: https://doi.org/https://doi.org/10.1093/ije/dyu094Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924–32. doi: https://doi.org/10.1097/GME.0000000000000196Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924–32. doi: https://doi.org/10.1097/GME.0000000000000196Costanian C, Zangiabadi S, Bahous SA, Deonandan R, Tamim H. Reviewing the evidence on vasomotor symptoms: the role of traditional and non-traditional factors. Climacteric. 2020;23(3):213–23. doi: https://doi.org/10.1080/13697137.2019.1711051Costanian C, Zangiabadi S, Bahous SA, Deonandan R, Tamim H. Reviewing the evidence on vasomotor symptoms: the role of traditional and non-traditional factors. Climacteric. 2020;23(3):213–23. doi: https://doi.org/10.1080/13697137.2019.1711051Prior JC. Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause. Facts, Views & Vision in ObGyn. 2011;3(2):109–20Prior JC. Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause. Facts, Views & Vision in ObGyn. 2011;3(2):109–20Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinology and Metabolism Clinics of North America. 2015;44(3):497–515. doi: https://doi.org/10.1016/j.ecl.2015.05.001Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinology and Metabolism Clinics of North America. 2015;44(3):497–515. doi: https://doi.org/10.1016/j.ecl.2015.05.001Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., Торопцова Н.В., Алексеева Л.И., Бирюкова Е.В., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. // Проблемы эндокринологии. — 2017. — Т.63. — №6. — С.392-426 doi: https://doi.org/10.14341/probl2017636392-426Mel’nichenko GA, Belaya JE, Rozhinskaya LYa, Toroptsova NV, Alekseeva LI, Biryukova EV, et al. Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problems of Endocrinology. 2017;63(6):392–426 doi: https://doi.org/10.14341/probl2017636392-426Muka T, Oliver-Williams C, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, et al. Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis. PLOS ONE. 2016;11(6):e0157417. doi: https://doi.org/10.1371/journal.pone.0157417Muka T, Oliver-Williams C, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, et al. Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis. PLOS ONE. 2016;11(6):e0157417. doi: https://doi.org/10.1371/journal.pone.0157417Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50. doi: https://doi.org/10.3109/13697137.2015.1129166Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50. doi: https://doi.org/10.3109/13697137.2015.1129166Kaufman MR, Ackerman AL, Amin KA, Coffey M, Danan E, Faubion SS, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. Journal of Urology. 2025;214(3):242–50. doi: https://doi.org/10.1097/JU.0000000000004589Kaufman MR, Ackerman AL, Amin KA, Coffey M, Danan E, Faubion SS, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. Journal of Urology. 2025;214(3):242–50. doi: https://doi.org/10.1097/JU.0000000000004589The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–92. doi: https://doi.org/10.1097/GME.0000000000001609The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–92. doi: https://doi.org/10.1097/GME.0000000000001609Rueda C, Osorio AM, Avellaneda AC, Pinzon CE, Restrepo OI. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017;20(4):321–30. doi: https://doi.org/10.1080/13697137.2017.1329291Rueda C, Osorio AM, Avellaneda AC, Pinzon CE, Restrepo OI. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017;20(4):321–30. doi: https://doi.org/10.1080/13697137.2017.1329291Hirschberg AL, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas. 2021;148:55–61. doi: https://doi.org/10.1016/j.maturitas.2021.04.005Hirschberg AL, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas. 2021;148:55–61. doi: https://doi.org/10.1016/j.maturitas.2021.04.005Weidlinger S, Schmutz C, Janka H, Gruetter C, Stute P. Sustainability of vaginal estrogens for genitourinary syndrome of menopause – a systematic review. Climacteric. 2021;24(6):551–9. doi: https://doi.org/10.1080/13697137.2021.1891218Weidlinger S, Schmutz C, Janka H, Gruetter C, Stute P. Sustainability of vaginal estrogens for genitourinary syndrome of menopause – a systematic review. Climacteric. 2021;24(6):551–9. doi: https://doi.org/10.1080/13697137.2021.1891218Matarazzo MG, Sarpietro G, Fiorito D, Di Pasqua S, Ingrassano S, Panella MM, et al. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021;263:67–71. doi: https://doi.org/10.1016/j.ejogrb.2021.06.009Matarazzo MG, Sarpietro G, Fiorito D, Di Pasqua S, Ingrassano S, Panella MM, et al. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021;263:67–71. doi: https://doi.org/10.1016/j.ejogrb.2021.06.009Duarte PR, Maroto Martin MT, Mar Martin Moya MD, Prados PA. Quality of life analysis measured with the Cervantes 16 scale in treated menopausal women with genitourinary syndrome. Journal of Comparative Effectiveness Research. 2022;11(18):1365–74. doi: https://doi.org/10.2217/cer-2022-0086Duarte PR, Maroto Martin MT, Mar Martin Moya MD, Prados PA. Quality of life analysis measured with the Cervantes 16 scale in treated menopausal women with genitourinary syndrome. Journal of Comparative Effectiveness Research. 2022;11(18):1365–74. doi: https://doi.org/10.2217/cer-2022-0086Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. 2019;26(2):220–4. doi: https://doi.org/10.1097/GME.0000000000001177Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. 2019;26(2):220–4. doi: https://doi.org/10.1097/GME.0000000000001177Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2018;25(11):1339–53. doi: https://doi.org/10.1097/GME.0000000000001238Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2018;25(11):1339–53. doi: https://doi.org/10.1097/GME.0000000000001238Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017;24(11):1246–56. doi: https://doi.org/10.1097/GME.0000000000000910Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017;24(11):1246–56. doi: https://doi.org/10.1097/GME.0000000000000910Cappola AR, Auchus RJ, El-Hajj Fuleihan G, Handelsman DJ, Kalyani RR, McClung M, et al. Hormones and Aging: An Endocrine Society Scientific Statement. The Journal of Clinical Endocrinology & Metabolism. 2023;108(8):1835–74. doi: https://doi.org/10.1210/clinem/dgad225Cappola AR, Auchus RJ, El-Hajj Fuleihan G, Handelsman DJ, Kalyani RR, McClung M, et al. Hormones and Aging: An Endocrine Society Scientific Statement. The Journal of Clinical Endocrinology & Metabolism. 2023;108(8):1835–74. doi: https://doi.org/10.1210/clinem/dgad225Серов В.Н., Баранов И.И., Андреева Е.Н., Абашова Е.И., Аганезова Н.В., Беженарь В.Ф. и др. Объединенная позиция российских экспертов по вопросу клинического значения гиперандрогении у женщин в ранней постменопаузе. // Акушерство и гинекология. — 2025. — №5. — С.201-6 doi: https://doi.org/10.18565/aig.2025.118Serov VN, Baranov II, Andreeva EN, Abashova EI, Aganezova NV, Bezhenar VF, et al. Joint position of Russian experts on the clinical significance of hyperandrogenism in early postmenopausal women. Obstetrics and gynecology. 2025;5:201–6 (In Russ.). doi: https://doi.org/10.18565/aig.2025.118Gluvic Z, Zaric B, Resanovic I, Obradovic M, Mitrovic A, Radak D, et al. Link between Metabolic Syndrome and InsulinResistance. Current Vascular Pharmacology. 2016;15(1):30–9. doi: https://doi.org/10.2174/1570161114666161007164510Gluvic Z, Zaric B, Resanovic I, Obradovic M, Mitrovic A, Radak D, et al. Link between Metabolic Syndrome and InsulinResistance. Current Vascular Pharmacology. 2016;15(1):30–9. doi: https://doi.org/10.2174/15701 61114666161007164510Stefanska A, Bergmann K, Sypniewska G. Metabolic Syndrome and Menopause: pathophysiology, clinical and diagnostic significance. Advances in Clinical Chemistry. 2015;72:1–75. doi: https://doi.org/10.1016/bs.acc.2015.07.001Stefanska A, Bergmann K, Sypniewska G. Metabolic Syndrome and Menopause: pathophysiology, clinical and diagnostic significance. Advances in Clinical Chemistry. 2015;72:1–75. doi: https://doi.org/10.1016/bs.acc.2015.07.001Hirschberg AL. Hyperandrogenism and Cardiometabolic Risk in Preand Postmenopausal Women – What Is the Evidence? The Journal of Clinical Endocrinology & Metabolism. 2024;109(5):1202–13. doi: https://doi.org/10.1210/clinem/dgad590Hirschberg AL. Hyperandrogenism and Cardiometabolic Risk in Preand Postmenopausal Women – What Is the Evidence? The Journal of Clinical Endocrinology & Metabolism. 2024;109(5):1202–13. doi: https://doi.org/10.1210/clinem/dgad590Hirschberg AL. Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman. The Journal of Clinical Endocrinology & Metabolism. 2023;108(5):1243–53. doi: https://doi.org/10.1210/clinem/dgac673Hirschberg AL. Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman. The Journal of Clinical Endocrinology & Metabolism. 2023;108(5):1243–53. doi: https://doi.org/10.1210/clinem/dgac673Frederiksen H, Johannsen TH, Andersen SE, Petersen JH, Busch AS, Ljubicic ML, et al. Sex- and age-specific reference intervals of 16 steroid metabolites quantified simultaneously by LC-MS/MS in sera from 2458 healthy subjects aged 0 to 77 years. Clinica Chimica Acta. 2024;562:119852. doi: https://doi.org/10.1016/j.cca.2024.119852Frederiksen H, Johannsen TH, Andersen SE, Petersen JH, Busch AS, Ljubicic ML, et al. Sex- and age-specific reference intervals of 16 steroid metabolites quantified simultaneously by LC-MS/MS in sera from 2458 healthy subjects aged 0 to 77 years. Clinica Chimica Acta. 2024;562:119852. doi: https://doi.org/10.1016/j.cca.2024.119852Torrens JI, Sutton-Tyrrell K, Zhao X, Matthews K, Brockwell S, Sowers M, et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: Study of Women’s Health Across the Nation. Menopause. 2009;16(2):257–64. doi: https://doi.org/10.1097/gme.0b013e318185e249Torrens JI, Sutton-Tyrrell K, Zhao X, Matthews K, Brockwell S, Sowers M, et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: Study of Women’s Health Across the Nation. Menopause. 2009;16(2):257–64. doi: https://doi.org/10.1097/gme.0b013e318185e249Alemany M. The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health. International Journal of Molecular Sciences. 2022;23(19):11952. doi: https://doi.org/10.3390/ijms231911952Alemany M. The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health. International Journal of Molecular Sciences. 2022;23(19):11952. doi: https://doi.org/10.3390/ijms231911952Galmes-Pascual BM, Martinez-Cignoni MR, Moran-Costoya A, Bauza-Thorbrugge M, Sbert-Roig M, Valle A, et al. 17β-estradiol ameliorates lipotoxicity-induced hepatic mitochondrial oxidative stress and insulin resistance. Free Radical Biology and Medicine. 2020;150:148– 60. doi: https://doi.org/10.1016/j.freeradbiomed.2020.02.016Galmes-Pascual BM, Martinez-Cignoni MR, Moran-Costoya A, Bauza-Thorbrugge M, Sbert-Roig M, Valle A, et al. 17β-estradiol ameliorates lipotoxicity-induced hepatic mitochondrial oxidative stress and insulin resistance. Free Radical Biology and Medicine. 2020;150:148– 60. doi: https://doi.org/10.1016/j.freeradbiomed.2020.02.016Nestler JE, Jakubowicz DJ, Falcon De Vargas A, Brik C, Quintero N, Medina F. Insulin Stimulates Testosterone Biosynthesis by Human Thecal Cells from Women with Polycystic Ovary Syndrome by Activating Its Own Receptor and Using Inositolglycan Mediators as the Signal Transduction System. The Journal of Clinical Endocrinology & Metabolism. 1998;83(6):2001–5. doi: https://doi.org/10.1210/jcem.83.6.4886Nestler JE, Jakubowicz DJ, Falcon De Vargas A, Brik C, Quintero N, Medina F. Insulin Stimulates Testosterone Biosynthesis by Human Thecal Cells from Women with Polycystic Ovary Syndrome by Activating Its Own Receptor and Using Inositolglycan Mediators as the Signal Transduction System. The Journal of Clinical Endocrinology & Metabolism. 1998;83(6):2001–5. doi: https://doi.org/10.1210/jcem.83.6.4886Xing C, Zhang J, Zhao H, He B. Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome:Mechanisms, Manifestations, Genetics, and Treatment. International Journal of Women’s Health. 2022;14:91–105. doi: https://doi.org/10.2147/IJWH.S344542Xing C, Zhang J, Zhao H, He B. Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome:Mechanisms, Manifestations, Genetics, and Treatment. International Journal of Women’s Health. 2022;14:91–105. doi: https://doi.org/10.2147/IJWH.S344542Dicker A, Ryden M, Naslund E, Muehlen IE, Wiren M, Lafontan M, et al. Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia. 2004;47(3):420–8. doi: https://doi.org/10.1007/s00125-003-1324-0Dicker A, Ryden M, Naslund E, Muehlen IE, Wiren M, Lafontan M, et al. Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia. 2004;47(3):420–8. doi: https://doi.org/10.1007/s00125-003-1324-0Zang H, Ryden M, Wahlen K, Dahlman-Wright K, Arner P, Hirschberg AL. Effects of testosterone and estrogen treatment on lipolysis signaling pathways in subcutaneous adipose tissue of postmenopausal women. Fertility and Sterility. 2007;88(1):100–6. doi: https://doi.org/10.1016/j.fertnstert.2006.11.088Zang H, Ryden M, Wahlen K, Dahlman-Wright K, Arner P, Hirschberg AL. Effects of testosterone and estrogen treatment on lipolysis signaling pathways in subcutaneous adipose tissue of postmenopausal women. Fertility and Sterility. 2007;88(1):100–6. doi: https://doi.org/10.1016/j.fertnstert.2006.11.088Grundy SM. Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor. The Journal of Clinical Endocrinology & Metabolism. 2007;92(2):399–404. doi: https://doi.org/10.1210/jc.2006-0513Grundy SM. Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor. The Journal of Clinical Endocrinology & Metabolism. 2007;92(2):399–404. doi: https://doi.org/10.1210/jc.2006-0513Hu G, The DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia. 2003;46(5):608–17. doi: https://doi.org/10.1007/s00125-003-1096-6Hu G, The DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia. 2003;46(5):608–17. doi: https://doi.org/10.1007/s00125-003-1096-6Министерство здравоохранения Российской Федерации. Клинические рекомендации. Сахарный диабет 2 типа у взрослых. 2022. Доступно на: https://cr.minzdrav.gov.ru/preview-cr/290_2Ministry of Health of Russian Federation. Clinical guidelines. Type 2 diabetes mellitus in adults. 2022. Av. at: https://cr.minzdrav.gov.ru/preview-cr/290_2Zhang L, Bao L, Li Y, Wang C, Dong X, Abdulai T, et al. Age at menopause, body mass index, and risk of type 2 diabetes mellitus in postmenopausal Chinese women: The Henan Rural Cohort study. Nutrition, Metabolism and Cardiovascular Diseases. 2020;30(8):1347–54. doi: https://doi.org/10.1016/j.numecd.2020.04.003Zhang L, Bao L, Li Y, Wang C, Dong X, Abdulai T, et al. Age at menopause, body mass index, and risk of type 2 diabetes mellitus in postmenopausal Chinese women: The Henan Rural Cohort study. Nutrition, Metabolism and Cardiovascular Diseases. 2020;30(8):1347–54. doi: https://doi.org/10.1016/j.numecd.2020.04.003Opoku AA, Abushama M, Konje JC. Obesity and menopause. Best Practice & Research Clinical Obstetrics & Gynaecology. 2023;88:102348. doi: https://doi.org/10.1016/j.bpobgyn.2023.102348Opoku AA, Abushama M, Konje JC. Obesity and menopause. Best Practice & Research Clinical Obstetrics & Gynaecology. 2023;88:102348. doi: https://doi.org/10.1016/j.bpobgyn.2023.102348Vishram JKK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jorgensen T, et al. Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project. PLoS ONE. 2014;9(9):e107294. doi: https://doi.org/10.1371/journal.pone.0107294Vishram JKK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jorgensen T, et al. Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project. PLoS ONE. 2014;9(9):e107294. doi: https://doi.org/10.1371/journal.pone.0107294Lizcano F, Guzman G. Estrogen Deficiency and the Origin of Obesity during Menopause. BioMed Research International. 2014;2014:757461. doi: https://doi.org/10.1155/2014/757461Lizcano F, Guzman G. Estrogen Deficiency and the Origin of Obesity during Menopause. BioMed Research International. 2014;2014:757461. doi: https://doi.org/10.1155/2014/757461Zhu J, Zhou Y, Jin B, Shu J. Role of estrogen in the regulation of central and peripheral energy homeostasis: from a menopausal perspective. Therapeutic Advances in Endocrinology and Metabolism. 2023;14:20420188231199359. doi: https://doi.org/10.1177/20420188231199359Zhu J, Zhou Y, Jin B, Shu J. Role of estrogen in the regulation of central and peripheral energy homeostasis: from a menopausal perspective. Therapeutic Advances in Endocrinology and Metabolism. 2023;14:20420188231199359. doi: https://doi.org/10.1177/20420188231199359Драпкина О.М., Концевая А.В., Калинина А.М., Авдеев С.Н., Агальцов М.В. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. // Кардиоваскулярная терапия и профилактика. — 2022. — Т.21. — №4. — С.5-232. doi: https://doi.org/10.15829/1728-8800-2022-3235Drapkina OM, Kontsevaya AV, Kalinina AM, Avdeev SN, Agaltsov MV, Alexandrova LM, et al. 2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):5– 232 (In Russ.) doi: https://doi.org/10.15829/1728-8800-2022-3235Юренева С.В. Ожирение в период менопаузального перехода: как прервать негативные связи и предупредить последствия? // Акушерство и гинекология. — 2024. — №11. — С.56-65. doi: https://doi.org/10.18565/aig.2024.291Yureneva SV. Obesity during the menopausal transition: how to break negative connections and prevent consequences? Obstetrics and Gynecology. 2024;11:56–65 (In Russ.) doi: https://doi.org/10.18565/aig.2024.291Chen G-C, Arthur R, Iyengar NM, Kamensky V, Xue X, WassertheilSmoller S, et al. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. European Heart Journal. 2019;40(34):2849–55. doi: https://doi.org/10.1093/eurheartj/ehz391Chen G-C, Arthur R, Iyengar NM, Kamensky V, Xue X, WassertheilSmoller S, et al. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. European Heart Journal. 2019;40(34):2849–55. doi: https://doi.org/10.1093/eurheartj/ehz391Министерство здравоохранения Российской Федерации. Клинические рекомендации. Ожирение. 2024. Доступно на: https://cr.minzdrav.gov.ru/preview-cr/28_3Ministry of Health of Russian Federation. Clinical recommendations. Obesity. 2024. Av. at: https://cr.minzdrav.gov.ru/preview-cr/28_3]Министерство здравоохранения Российской Федерации. Клинические рекомендации. Артериальная гипертензия у взрослых. 2024. Доступно на: https://cr.minzdrav.gov.ru/preview-cr/62_3Ministry of Health of Russian Federation. Clinical guidelines. Arterial hypertension in adults. 2024. Av. at: https://cr.minzdrav.gov.ru/preview-cr/62_3Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. The Lancet. 2005;366(9491):1059–62. doi: https://doi.org/10.1016/S0140-6736(05)67402-8Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. The Lancet. 2005;366(9491):1059–62. doi: https://doi.org/10.1016/S0140-6736(05)67402-8Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sciences. 2019;236:116940. doi: https://doi.org/10.1016/j.lfs.2019.116940Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sciences. 2019;236:116940. doi: https://doi.org/10.1016/j.lfs.2019.116940Cushman M. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA. 2004;292(13):1573–80. doi: https://doi.org/10.1001/jama.292.13.1573Cushman M. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA. 2004;292(13):1573–80. doi: https://doi.org/10.1001/jama.292.13.1573Трошина Е.А., Покусаева В.Н., Андреева Е.Н. Ожирение у женщин. под ред. Мельниченко Г.А., Никифоровского Н.К. - М.: ООО Медицинское информационное агентство; 2017. – 272с ISBN 978-5-9986-0296-2Troshina EA, Pokusaeva VN, Andreeva EN. Obesity in women. edited by Melnichenko G.A., Nikiforovskii N.K. - M.: Medical Information Agency LLC; 2017. - 272pCaprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V, et al. Antiadipogenic Effects of the Mineralocorticoid Receptor Antagonist Drospirenone: Potential Implications for the Treatment of Metabolic Syndrome. Endocrinology. 2011;152(1):113–25. doi: https://doi.org/10.1210/en.2010-0674Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V, et al. Antiadipogenic Effects of the Mineralocorticoid Receptor Antagonist Drospirenone: Potential Implications for the Treatment of Metabolic Syndrome. Endocrinology. 2011;152(1):113–25. doi: https://doi.org/10.1210/en.2010-0674Сметник А.А., Иванов И.А., Ермакова Е.И., Табеева Г.И. Особенности использования менопаузальной гормональной терапии в России: результаты масштабного опроса женщин в пери- и постменопаузе. // Акушерство и гинекология. — 2025. — №8. — С.196-208. doi: https://doi.org/10.18565/aig.2025.200Smetnik AA, Ivanov IA, Ermakova EI, Tabeeva GI. Characteristics of menopausal hormone therapy use in Russia: results of a largescale survey of peri- and postmenopausal women. Obstetrics and gynecology. 2025;8:196–208 doi: https://doi.org/10.18565/aig.2025.200Сухих Г.Т., Серов В.Н., Шляхто Е.В., Дедов И.И., Арутюнов Г.П., Ткачева О.Н. и др. Менопаузальная гормональная терапия у пациенток с сердечно-сосудистыми и метаболическими заболеваниями: междисциплинарный дельфийский консенсус среди российских гинекологов, кардиологов, эндокринологов, геронтологов и гериатров, флебологов, клинических фармакологов. // Терапевтический архив. — 2026. — Т.98. — №1. — С.6–27. doi: https://doi.org/10.26442/00403660.2026.01.203470Sukhikh GT, Serov VN, Shlyakhto EV, Dedov II, Arutyunov GP, Tkacheva ON, et al. Consensus Menopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists. Therapeutic Archive. 2026;98(1):6–27 doi: https://doi.org/10.26442/00403660.2026.01.203470Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. // Сахарный диабет. — 2021. — Т.24. — №3. — С.204-21. doi: https://doi.org/10.14341/DM12759Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204–21 (In Russ.) doi: https://doi.org/10.14341/DM12759Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism. 2006;8(5):538–54. doi: https://doi.org/10.1111/j.1463-1326.2005.00545.xSalpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism. 2006;8(5):538–54. doi: https://doi.org/10.1111/j.1463-1326.2005.00545.xSchindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1–2):171–80. doi: https://doi.org/10.1016/j.maturitas.2008.11.013Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1–2):171–80. doi: https://doi.org/10.1016/j.maturitas.2008.11.013Mendoza N, Ramirez I, De La Viuda E, Coronado P, Baquedano L, Llaneza P, et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022;166:65–85. doi: https://doi.org/10.1016/j.maturitas.2022.08.008Mendoza N, Ramirez I, De La Viuda E, Coronado P, Baquedano L, Llaneza P, et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022;166:65–85. doi: https://doi.org/10.1016/j.maturitas.2022.08.008De Filippis A, Ullah H, Baldi A, Dacrema M, Esposito C, Garzarella EU, et al. Gastrointestinal Disorders and Metabolic Syndrome: Dysbiosis as a Key Link and Common Bioactive Dietary Components Useful for their Treatment. International Journal of Molecular Sciences. 2020;21(14):4929. doi: https://doi.org/10.3390/ijms21144929De Filippis A, Ullah H, Baldi A, Dacrema M, Esposito C, Garzarella EU, et al. Gastrointestinal Disorders and Metabolic Syndrome: Dysbiosis as a Key Link and Common Bioactive Dietary Components Useful for their Treatment. International Journal of Molecular Sciences. 2020;21(14):4929. doi: https://doi.org/10.3390/ijms21144929Zuvarox T, Goosenberg E, Belletieri C. Malabsorption Syndromes. In: StatPearls-Treasure Island (FL): StatPearls Publishing; 2025Zuvarox T, Goosenberg E, Belletieri C. Malabsorption Syndromes. In: StatPearls-Treasure Island (FL): StatPearls Publishing; 2025Elkafas H, Walls M, Al-Hendy A, Ismail N. Gut and genital tract microbiomes: Dysbiosis and link to gynecological disorders. Frontiers in Cellular and Infection Microbiology. 2022;12:1059825. doi: https://doi.org/10.3389/fcimb.2022.1059825Elkafas H, Walls M, Al-Hendy A, Ismail N. Gut and genital tract microbiomes: Dysbiosis and link to gynecological disorders. Frontiers in Cellular and Infection Microbiology. 2022;12:1059825. doi: https://doi.org/10.3389/fcimb.2022.1059825Xie X, Song J, Wu Y, Li M, Guo W, Li S, et al. Study on gut microbiota and metabolomics in postmenopausal women. BMC Women’s Health. 2024;24(1):608. doi: https://doi.org/10.1186/s12905-024-03448-7Xie X, Song J, Wu Y, Li M, Guo W, Li S, et al. Study on gut microbiota and metabolomics in postmenopausal women. BMC Women’s Health. 2024;24(1):608. doi: https://doi.org/10.1186/s12905-024-03448-7The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–94. doi: https://doi.org/10.1097/GME.0000000000002028The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–94. doi: https://doi.org/10.1097/GME.0000000000002028Kim J-E, Chang J-H, Jeong M-J, Choi J, Park J, Baek C, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Scientific Reports. 2020;10(1):20631. doi: https://doi.org/10.1038/s41598-020-77534-9Kim J-E, Chang J-H, Jeong M-J, Choi J, Park J, Baek C, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Scientific Reports. 2020;10(1):20631. doi: https://doi.org/10.1038/s41598-020-77534-9Boardman HM, Hartley L, Eisinga A, Main C, Roque I Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews. 2015;2015(8):CD002229. doi: https://doi.org/10.1002/14651858.CD002229.pub4Boardman HM, Hartley L, Eisinga A, Main C, Roque I Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews. 2015;2015(8):CD002229. doi: https://doi.org/10.1002/14651858.CD002229.pub4Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. doi: https://doi.org/10.1136/bmj.k4810Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. doi: https://doi.org/10.1136/bmj.k4810Goldštajn MŠ, Mikuš M, Ferrari FA, Bosco M, Uccella S, Noventa M, et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Archives of Gynecology and Obstetrics. 2022;307(6):1727–45. doi: https://doi.org/10.1007/s00404-022-06647-5Goldštajn MŠ, Mikuš M, Ferrari FA, Bosco M, Uccella S, Noventa M, et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Archives of Gynecology and Obstetrics. 2022;307(6):1727–45. doi: https://doi.org/10.1007/s00404-022-06647-5Kapoor E, Kling JM, Lobo AS, Faubion SS. Menopausal hormone therapy in women with medical conditions. Best Practice & Research Clinical Endocrinology & Metabolism. 2021;35(6):101578. doi: https://doi.org/10.1016/j.beem.2021.101578Kapoor E, Kling JM, Lobo AS, Faubion SS. Menopausal hormone therapy in women with medical conditions. Best Practice & Research Clinical Endocrinology & Metabolism. 2021;35(6):101578. doi: https://doi.org/10.1016/j.beem.2021.101578Morris G, Talaulikar V. Hormone replacement therapy in women with history of thrombosis or a thrombophilia. Post Reproductive Health. 2023;29(1):33–41. doi: https://doi.org/10.1177/20533691221148036Morris G, Talaulikar V. Hormone replacement therapy in women with history of thrombosis or a thrombophilia. Post Reproductive Health. 2023;29(1):33–41. doi: https://doi.org/10.1177/20533691221148036Dinger J, Bardenheuer K, Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349–56. doi: https://doi.org/10.1080/13697137.2016.1183624Dinger J, Bardenheuer K, Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349–56. doi: https://doi.org/10.1080/13697137.2016.1183624Sobel TH, Shen W. Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review. Menopause. 2022;29(4):483–90. doi: https://doi.org/10.1097/GME.0000000000001938Sobel TH, Shen W. Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review. Menopause. 2022;29(4):483–90. doi: https://doi.org/10.1097/GME.0000000000001938Roetker N, MacLehose R, Hoogeveen R, Ballantyne C, Basu S, Cushman M, et al. Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study. Thrombosis and Haemostasis. 2018;118(11):1940–50. doi: https://doi.org/10.1055/s-0038-1673613Roetker N, MacLehose R, Hoogeveen R, Ballantyne C, Basu S, Cushman M, et al. Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study. Thrombosis and Haemostasis. 2018;118(11):1940–50. doi: https://doi.org/10.1055/s-0038-1673613Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678–700. doi: https://doi.org/10.1016/j.contraception.2016.04.014Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678–700. doi: https://doi.org/10.1016/j.contraception.2016.04.014Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944. doi: https://doi.org/10.1136/bmj.e4944Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944. doi: https://doi.org/10.1136/bmj.e4944Nudy M, Chinchilli VM, Foy AJ. A systematic review and metaregression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. IJC Heart & Vasculature. 2019;22:123–31. doi: https://doi.org/10.1016/j.ijcha.2019.01.001Nudy M, Chinchilli VM, Foy AJ. A systematic review and metaregression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. IJC Heart & Vasculature. 2019;22:123–31. doi: https://doi.org/10.1016/j.ijcha.2019.01.001Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N, et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. 2023;147(7):597–610. doi: https://doi.org/10.1161/CIRCULATIONAHA.122.061559Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N, et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. 2023;147(7):597–610. doi: https://doi.org/10.1161/CIRCULATIONAHA.122.061559LaVasseur C, Neukam S, Kartika T, Samuelson Bannow B, Shatzel J, DeLoughery TG. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Research and Practice in Thrombosis and Haemostasis. 2022;6(6):e12763. doi: https://doi.org/10.1002/rth2.12763LaVasseur C, Neukam S, Kartika T, Samuelson Bannow B, Shatzel J, DeLoughery TG. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Research and Practice in Thrombosis and Haemostasis. 2022;6(6):e12763. doi: https://doi.org/10.1002/rth2.12763Roach REJ, Lijfering WM, Van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR, Cannegieter SC. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood. 2013;122(26):4264–9. doi: https://doi.org/10.1182/blood-2013-07-518159Roach REJ, Lijfering WM, Van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR, Cannegieter SC. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood. 2013;122(26):4264–9. doi: https://doi.org/10.1182/blood-2013-07-518159Straczek C, Oger E, Yon De Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al. Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration. Circulation. 2005;112(22):3495–500. doi: https://doi.org/10.1161/CIRCULATIONAHA.105.565556Straczek C, Oger E, Yon De Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al. Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration. Circulation. 2005;112(22):3495–500. doi: https://doi.org/10.1161/CIRCULATIONAHA.105.565556Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, Coppens M, Houghton D, James AH, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Advances. 2023;7(22):7101–38. doi: https://doi.org/10.1182/bloodadvances.2023010177Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, Coppens M, Houghton D, James AH, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Advances. 2023;7(22):7101–38. doi: https://doi.org/10.1182/bloodadvances.2023010177Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest. 2012;141(2):7S-47S. doi: https://doi.org/10.1378/chest.1412S3Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest. 2012;141(2):7S-47S. doi: https://doi.org/10.1378/chest.1412S3Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–13. doi: https://doi.org/10.1001/jama.280.7.605Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–13. doi: https://doi.org/10.1001/jama.280.7.605Yuk J-S, Kim GS, Kim D-G, Byun YS, Kim M-H, Yoon S-H, et al. Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women. European Journal of Endocrinology. 2025;192(2):73–80. doi: https://doi.org/10.1093/ejendo/lvae161Yuk J-S, Kim GS, Kim D-G, Byun YS, Kim M-H, Yoon S-H, et al. Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women. European Journal of Endocrinology. 2025;192(2):73–80. doi: https://doi.org/10.1093/ejendo/lvae161Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women’s Health Initiative: A Randomized Trial. JAMA. 2003;289(20):2673–84. doi: https://doi.org/10.1001/jama.289.20.2673Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women’s Health Initiative: A Randomized Trial. JAMA. 2003;289(20):2673–84. doi: https://doi.org/10.1001/jama.289.20.2673Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al. Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative. Circulation. 2006;113(20):2425–34. doi: https://doi.org/10.1161/CIRCULATIONAHA.105.594077Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al. Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative. Circulation. 2006;113(20):2425–34. doi: https://doi.org/10.1161/CIRCULATIONAHA.105.594077Te West NID, Day RO, Hiley B, White C, Wright M, Moore KH. Estriol serum levels in new and chronic users of vaginal estriol cream: A prospective observational study. Neurourology and Urodynamics. 2020;39(4):1137–44. doi: https://doi.org/10.1002/nau.24331Te West NID, Day RO, Hiley B, White C, Wright M, Moore KH. Estriol serum levels in new and chronic users of vaginal estriol cream: A prospective observational study. Neurourology and Urodynamics. 2020;39(4):1137–44. doi: https://doi.org/10.1002/nau.24331Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361–70. doi: https://doi.org/10.1097/GME.0000000000001463Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361–70. doi: https://doi.org/10.1097/GME.0000000000001463Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2019;26(6):603–10. doi: https://doi.org/10.1097/GME.0000000000001284Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2019;26(6):603–10. doi: https://doi.org/10.1097/GME.0000000000001284Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20. doi: https://doi.org/10.1097/GME.0000000000000956Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20. doi: https://doi.org/10.1097/GME.0000000000000956Орлова Я.А., Плисюк А.Г., Долгушин Г.О., Кириллова К.И., Михеев Р.К., Андреева Е.Н. Связь длительной менопаузальной гормональной терапии и показателей сосудистого и репликативного старения у женщин. // Профилактическая медицина. — 2023. — Т.26. —№7. — С.96-102. doi: https://doi.org/10.17116/profmed20232607196Orlova YaA, Plisyuk AG, Dolgushin GO, Kirillova KI, Mikheev RK, Andreeva EN. Correlation between prolonged menopausal hormonotherapy and indicators of vascular and replicative aging in women. Prevention Medicine. 2023;26(7):96–102 (In Russ.) doi: https://doi.org/10.17116/profmed20232607196Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. Journal of Bone and Mineral Research. 2009;11(6):835–42. doi: https://doi.org/10.1002/jbmr.5650110615Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. Journal of Bone and Mineral Research. 2009;11(6):835–42. doi: https://doi.org/10.1002/jbmr.5650110615Nie G, Yang X, Wang Y, Liang W, Li X, Luo Q, et al. The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2022;13:850815. doi: https://doi.org/10.3389/fphar.2022.850815Nie G, Yang X, Wang Y, Liang W, Li X, Luo Q, et al. The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2022;13:850815. doi: https://doi.org/10.3389/fphar.2022.850815Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А.С., Анциферов М.Б., Аншелес А.А. и др. Нарушения липидного обмена. Клинические рекомендации 2023. // Российский кардиологический журнал. — 2023. — Т.28. — №5. — С.250-97. doi: https://doi.org/10.15829/1560-4071-2023-5471Ezhov MV, Kukharchuk VV, Sergienko IV, Alieva AS, Antsiferov MB, Ansheles AA, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250–97 (In Russ.) doi: https://doi.org/10.15829/1560-4071-2023-5471Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor:current status. European Heart Journal. 2010;31(23):2844–53. doi: https://doi.org/10.1093/eurheartj/ehq386Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor:current status. European Heart Journal. 2010;31(23):2844–53. doi: https://doi.org/10.1093/eurheartj/ehq386Honigberg MC, Trinder M, Natarajan P. Lipoprotein(a), Menopausal Hormone Therapy, and Risk of Coronary Heart Disease in Postmenopausal Individuals. JAMA Cardiology. 2022;7(5):565–8. doi: https://doi.org/10.1001/jamacardio.2022.0716Honigberg MC, Trinder M, Natarajan P. Lipoprotein(a), Menopausal Hormone Therapy, and Risk of Coronary Heart Disease in Postmenopausal Individuals. JAMA Cardiology. 2022;7(5):565–8. doi: https://doi.org/10.1001/jamacardio.2022.0716Stevenson JC, Chines A, Pan K, Ryan KA, Mirkin S. A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials. The Journal of Clinical Endocrinology & Metabolism. 2015;100(6):2329–38. doi: https://doi.org/10.1210/jc.2014-2649Stevenson JC, Chines A, Pan K, Ryan KA, Mirkin S. A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials. The Journal of Clinical Endocrinology & Metabolism. 2015;100(6):2329–38. doi: https://doi.org/10.1210/jc.2014-2649Miller VT, LaRosa J, Barnabei V, Kessler C, Levin G, Smith-Roth A, et al. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199–208. doi: https://doi.org/10.1001/jama.1995.03520270033028Miller VT, LaRosa J, Barnabei V, Kessler C, Levin G, Smith-Roth A, et al. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199–208. doi: https://doi.org/10.1001/jama.1995.03520270033028Binder EF, Birge SJ, Kohrt WM. Effects of Endurance Exercise and Hormone Replacement Therapy on Serum Lipids in Older Women. Journal of the American Geriatrics Society. 1996;44(3):231–6. doi: https://doi.org/10.1111/j.1532-5415.1996.tb00907.xBinder EF, Birge SJ, Kohrt WM. Effects of Endurance Exercise and Hormone Replacement Therapy on Serum Lipids in Older Women. Journal of the American Geriatrics Society. 1996;44(3):231–6. doi: https://doi.org/10.1111/j.1532-5415.1996.tb00907.xBunyavejchevin S, Limpaphayom KK. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a doubleblind placebo-controlled trial. Journal of the Medical Association of Thailand. 2001;84(1):45–53. PMID: 11281499Bunyavejchevin S, Limpaphayom KK. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a doubleblind placebo-controlled trial. Journal of the Medical Association of Thailand. 2001;84(1):45–53. PMID: 11281499Cayan F, Gen R, Akbay E, Dilek U, Dilek S. The Effect of Hormone Therapy and Tibolone on Glucose and Lipid Metabolism in Healthy Postmenopausal Women. Turkish Journal of Geriatrics. 2011;14(1):19– 25. [Av. at: https://geriatri.dergisi.org/abstract.php?id=534]Cayan F, Gen R, Akbay E, Dilek U, Dilek S. The Effect of Hormone Therapy and Tibolone on Glucose and Lipid Metabolism in Healthy Postmenopausal Women. Turkish Journal of Geriatrics. 2011;14(1):19– 25. [Av. at: https://geriatri.dergisi.org/abstract.php?id=534]Cheng GJ, Liu JL, Zhang Q, Fan W, Ye HF, Wang ZQ, et al. Nylestriol replacement therapy in postmenopausal women. A three-year prospective study. Chinese Medical Journal. 1993;106(12):911–6Cheng GJ, Liu JL, Zhang Q, Fan W, Ye HF, Wang ZQ, et al. Nylestriol replacement therapy in postmenopausal women. A three-year prospective study. Chinese Medical Journal. 1993;106(12):911–6Conard J, Basdevant A, Thomas J-L, Ochsenbein E, Denis C, Guyene TT, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertility and Sterility. 1995;64(5):957–62. doi: https://doi.org/10.1016/S0015-0282(16)57909-6Conard J, Basdevant A, Thomas J-L, Ochsenbein E, Denis C, Guyene TT, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertility and Sterility. 1995;64(5):957–62. doi: https://doi.org/10.1016/S0015-0282(16)57909-6Conard J, Gompel A, Pelissier C, Mirabel C, Basdevant A. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertility and Sterility. 1997;68(3):449–53 doi: https://doi.org/10.1016/S0015-0282(97)00220-3Conard J, Gompel A, Pelissier C, Mirabel C, Basdevant A. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertility and Sterility. 1997;68(3):449–53 doi: https://doi.org/10.1016/S0015-0282(97)00220-3Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, et al. Effects of Continuous Estrogen and Estrogen-Progestin Replacement Regimens on Cardiovascular Risk Markers in Postmenopausal Women. Archives of Internal Medicine. 2000;160(21):3315–25. doi: https://doi.org/10.1001/archinte.160.21.3315Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, et al. Effects of Continuous Estrogen and Estrogen-Progestin Replacement Regimens on Cardiovascular Risk Markers in Postmenopausal Women. Archives of Internal Medicine. 2000;160(21):3315–25. doi: https://doi.org/10.1001/archinte.160.21.3315Duvernoy CS, Rose PA, Kim HM, Kehrer C, Brook RD. Combined Continuous Ethinyl Estradiol/Norethindrone Acetate Does Not Improve Forearm Blood Flow in Postmenopausal Women at Risk for Cardiovascular Events: A Pilot Study. Journal of Women’s Health. 2007;16(7):963–70. doi: https://doi.org/10.1089/jwh.2006.0321Duvernoy CS, Rose PA, Kim HM, Kehrer C, Brook RD. Combined Continuous Ethinyl Estradiol/Norethindrone Acetate Does Not Improve Forearm Blood Flow in Postmenopausal Women at Risk for Cardiovascular Events: A Pilot Study. Journal of Women’s Health. 2007;16(7):963–70. doi: https://doi.org/10.1089/jwh.2006.0321Casanova G, Dos Reis AM, Spritzer PM. Low-dose oral or nonoral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause. Climacteric. 2015;18(1):86–93. doi: https://doi.org/10.3109/13697137.2014.940309Casanova G, Dos Reis AM, Spritzer PM. Low-dose oral or nonoral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause. Climacteric. 2015;18(1):86–93. doi: https://doi.org/10.3109/13697137.2014.940309Haase CL, Tybj.rg-Hansen A, Ali Qayyum A, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals. Journal of Clinical Endocrinology & Metabolism. 2012;97(2):E248–56. doi: https://doi.org/10.1210/jc.2011-1846Haase CL, Tybj.rg-Hansen A, Ali Qayyum A, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals. Journal of Clinical Endocrinology & Metabolism. 2012;97(2):E248–56. doi: https://doi.org/10.1210/jc.2011-1846Lv C, Zhang W, Tan X, Shang X, Găman M-A, Salem H, et al. The effect of tibolone treatment on lipid profile in women: A systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacological Research. 2021;169:105612. doi: https://doi.org/10.1016/j.phrs.2021.105612Lv C, Zhang W, Tan X, Shang X, Găman M-A, Salem H, et al. The effect of tibolone treatment on lipid profile in women: A systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacological Research. 2021;169:105612. doi: https://doi.org/10.1016/j.phrs.2021.105612Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lambrinoudaki I, et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausalwomen: A systematic review and meta-analysis. Maturitas. 2017;99:27–36. doi: https://doi.org/10.1016/j.maturitas.2017.02.009Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lambrinoudaki I, et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausalwomen: A systematic review and meta-analysis. Maturitas. 2017;99:27–36. doi: https://doi.org/10.1016/j.maturitas.2017.02.009Falkeborn M, Persson I, Adami H-O, Bergstrom R, Eaker E, Lithell H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. British Journal of Obstetrics and Gynaecology. 1992;99(10):821–8. doi: https://doi.org/10.1111/j.1471-0528.1992.tb14414.xFalkeborn M, Persson I, Adami H-O, Bergstrom R, Eaker E, Lithell H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. British Journal of Obstetrics and Gynaecology. 1992;99(10):821–8. doi: https://doi.org/10.1111/j.1471-0528.1992.tb14414.xShufelt CL, Manson JE. Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery. The Journal of Clinical Endocrinology & Metabolism. 2021;106(5):1245–54. doi: https://doi.org/10.1210/clinem/dgab042Shufelt CL, Manson JE. Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery. The Journal of Clinical Endocrinology & Metabolism. 2021;106(5):1245–54. doi: https://doi.org/10.1210/clinem/dgab042Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020;135:82–8. doi: https://doi.org/10.1016/j.maturitas.2020.03.007Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020;135:82–8. doi: https://doi.org/10.1016/j.maturitas.2020.03.007Wenger NK, Lloyd-Jones DM, Elkind MSV, Fonarow GC, Warner JJ, Alger HM, et al. Call to Action for Cardiovascular Disease in Women: Epidemiology, Awareness, Access, and Delivery of Equitable Health Care: A Presidential Advisory From the American Heart Association. Circulation. 2022;145(23):e1059–71. doi: https://doi.org/10.1161/CIR.0000000000001071Wenger NK, Lloyd-Jones DM, Elkind MSV, Fonarow GC, Warner JJ, Alger HM, et al. Call to Action for Cardiovascular Disease in Women: Epidemiology, Awareness, Access, and Delivery of Equitable Health Care: A Presidential Advisory From the American Heart Association. Circulation. 2022;145(23):e1059–71. doi: https://doi.org/10.1161/CIR.0000000000001071Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. The Lancet. 2021;397(10292):2385–438. doi: https://doi.org/10.1016/S0140-6736(21)00684-XVogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. The Lancet. 2021;397(10292):2385–438. doi: https://doi.org/10.1016/S0140-6736(21)00684-XReckelhoff JF. Gender differences in hypertension: Current Opinion in Nephrology and Hypertension. 2018;27 (3):176–81. doi: https://doi.org/10.1097/MNH.0000000000000404Reckelhoff JF. Gender differences in hypertension: Current Opinion in Nephrology and Hypertension. 2018;27 (3):176–81. doi: https://doi.org/10.1097/MNH.0000000000000404Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, et al. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women. Journal of the American College of Cardiology. 2020;75(20):2602–18. doi: https://doi.org/10.1016/j.jacc.2020.03.060Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, et al. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women. Journal of the American College of Cardiology. 2020;75(20):2602–18. doi: https://doi.org/10.1016/j.jacc.2020.03.060Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, et al. Sex differences in arterial hypertension. European Heart Journal. 2022;43(46):4777–88. doi: https://doi.org/10.1093/eurheartj/ehac470Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, et al. Sex differences in arterial hypertension. European Heart Journal. 2022;43(46):4777–88. doi: https://doi.org/10.1093/eurheartj/ehac470Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021;398(10304):957–80. doi: https://doi.org/10.1016/S0140-6736(21)01330-1Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021;398(10304):957–80. doi: https://doi.org/10.1016/S0140-6736(21)01330-1O’Keeffe LM, Simpkin AJ, Tilling K, Anderson EL, Hughes AD, Lawlor DA, et al. Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: A prospective cohort study. Atherosclerosis. 2018;278:190–6. doi: https://doi.org/10.1016/j.atherosclerosis.2018.09.030O’Keeffe LM, Simpkin AJ, Tilling K, Anderson EL, Hughes AD, Lawlor DA, et al. Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: A prospective cohort study. Atherosclerosis. 2018;278:190–6. doi: https://doi.org/10.1016/j.atherosclerosis.2018.09.030Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN, et al. Sex Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiology. 2020;5(3):19–26. doi: https://doi.org/10.1001/jamacardio.2019.5306Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN, et al. Sex Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiology. 2020;5(3):19–26. doi: https://doi.org/10.1001/jamacardio.2019.5306Maas A, Rosano G, Cifkova R, Chieffo A, Van Dijken D, Hamoda H, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. European Heart Journal. 2021;42(10):967–84. doi: https://doi.org/10.1093/eurheartj/ehaa1044Maas A, Rosano G, Cifkova R, Chieffo A, Van Dijken D, Hamoda H, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. European Heart Journal. 2021;42(10):967–84. doi: https://doi.org/10.1093/eurheartj/ehaa1044El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506–32 doi: https://doi.org/10.1161/CIR.0000000000000912El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506–32 doi: https://doi.org/10.1161/CIR.0000000000000912Biglia N, Cagnacci A, Gambacciani M, Lello S, Maffei S, Nappi RE. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric. 2017;20(4):306– 12. doi: https://doi.org/10.1080/13697137.2017.1315089Biglia N, Cagnacci A, Gambacciani M, Lello S, Maffei S, Nappi RE. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric. 2017;20(4):306– 12. doi: https://doi.org/10.1080/13697137.2017.1315089Chapman N, Ching SM, Konradi AO, Nuyt AM, Khan T, Twumasi Ankrah B, et al. Arterial Hypertension in Women: State of the Art and Knowledge Gaps. Hypertension. 2023;80(6):1140–9. doi: https://doi.org/10.1161/HYPERTENSIONAHA.122.20448Chapman N, Ching SM, Konradi AO, Nuyt AM, Khan T, Twumasi Ankrah B, et al. Arterial Hypertension in Women: State of the Art and Knowledge Gaps. Hypertension. 2023;80(6):1140–9. doi: https://doi.org/10.1161/HYPERTENSIONAHA.122.20448Coutinho T. Arterial Stiffness and Its Clinical Implications in Women. Canadian Journal of Cardiology. 2014;30(7):756–64. doi: https://doi.org/10.1016/j.cjca.2014.03.020Coutinho T. Arterial Stiffness and Its Clinical Implications in Women. Canadian Journal of Cardiology. 2014;30(7):756–64. doi: https://doi.org/10.1016/j.cjca.2014.03.020Picone DS, Kodithuwakku V, Mayer CC, Chapman N, Rehman S, Climie RE. Sex differences in pressure and flow waveform physiology across the life course. Journal of Hypertension. 2022;40(12):2373–84. doi: https://doi.org/10.1097/HJH.0000000000003283Picone DS, Kodithuwakku V, Mayer CC, Chapman N, Rehman S, Climie RE. Sex differences in pressure and flow waveform physiology across the life course. Journal of Hypertension. 2022;40(12):2373–84. doi: https://doi.org/10.1097/HJH.0000000000003283Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, LloydJones DM, et al. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women – 2011 Update: A Guideline From the American Heart Association. Circulation. 2011;123(11):1243–62. doi: https://doi.org/10.1161/CIR.0b013e31820faaf8Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, LloydJones DM, et al. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women – 2011 Update: A Guideline From the American Heart Association. Circulation. 2011;123(11):1243–62. doi: https://doi.org/10.1161/CIR.0b013e31820faaf8Issa Z, Seely EW, Rahme M, El-Hajj Fuleihan G. Effects of hormone therapy on blood pressure. Menopause. 2015;22(4):456–68. doi: https://doi.org/10.1097/GME.0000000000000322Issa Z, Seely EW, Rahme M, El-Hajj Fuleihan G. Effects of hormone therapy on blood pressure. Menopause. 2015;22(4):456–68. doi: https://doi.org/10.1097/GME.0000000000000322Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension. 2023;41(12):1874–2071. doi: https://doi.org/10.1097/HJH.0000000000003480Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension. 2023;41(12):1874–2071. doi: https://doi.org/10.1097/HJH.0000000000003480Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. // Российский кардиологический журнал. — 2020. — Т.25. — №3. — С.149-218. [Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149– 218 (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2020-3-3786Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149– 218 (In Russ.) doi: https://doi.org/10.15829/1560-4071-2020-3-3786Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Archives of Internal Medicine. 2006;166(7):772–80. doi: https://doi.org/10.1001/archinte.166.7.772Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Archives of Internal Medicine. 2006;166(7):772–80. doi: https://doi.org/10.1001/archinte.166.7.772Blondon M, Wiggins KL, Van Hylckama Vlieg A, McKnight B, Psaty BM, Rice KM, et al. Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population‐based, case–control study. British Journal of Haematology. 2013;163(3):418–20. doi: https://doi.org/10.1111/bjh.12508Blondon M, Wiggins KL, Van Hylckama Vlieg A, McKnight B, Psaty BM, Rice KM, et al. Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population‐based, case–control study. British Journal of Haematology. 2013;163(3):418–20. doi: https://doi.org/10.1111/bjh.12508Ruan X, Mueck AO. Impact of smoking on estrogenic efficacy. Climacteric. 2015;18(1):38–46. doi: https://doi.org/10.3109/13697137.2014.929106Ruan X, Mueck AO. Impact of smoking on estrogenic efficacy. Climacteric. 2015;18(1):38–46. doi: https://doi.org/10.3109/13697137.2014.929106Schreinlechner M, Noflatscher M, Reinstadler SJ, Sommer P, Lener D, Reiser E, et al. Early onset of menopause is associated with increased peripheral atherosclerotic plaque volume and progression. Atherosclerosis. 2020;297:25–31. doi: https://doi.org/10.1016/j.atherosclerosis.2020.01.023Schreinlechner M, Noflatscher M, Reinstadler SJ, Sommer P, Lener D, Reiser E, et al. Early onset of menopause is associated with increased peripheral atherosclerotic plaque volume and progression. Atherosclerosis. 2020;297:25–31. doi: https://doi.org/10.1016/j.atherosclerosis.2020.01.023Rockman CB, Maldonado TS, Jacobowitz GR, Adelman MA, Riles TS. Hormone Replacement Therapy is Associated With a Decreased Prevalence of Peripheral Arterial Disease in Postmenopausal Women. Annals of Vascular Surgery. 2012;26(3):411–8. doi: https://doi.org/10.1016/j.avsg.2011.10.012Rockman CB, Maldonado TS, Jacobowitz GR, Adelman MA, Riles TS. Hormone Replacement Therapy is Associated With a Decreased Prevalence of Peripheral Arterial Disease in Postmenopausal Women. Annals of Vascular Surgery. 2012;26(3):411–8. doi: https://doi.org/10.1016/j.avsg.2011.10.012Westendorp I, In’T Veld BA, Grobbee DE, Pols H, Meijer WT, Hofman A, et al. Hormone Replacement Therapy and Peripheral Arterial Disease: The Rotterdam Study. Archives of Internal Medicine. 2000;160(16):2498–502. doi: https://doi.org/10.1001/archinte.160.16.2498Westendorp I, In’T Veld BA, Grobbee DE, Pols H, Meijer WT, Hofman A, et al. Hormone Replacement Therapy and Peripheral Arterial Disease: The Rotterdam Study. Archives of Internal Medicine. 2000;160(16):2498–502. doi: https://doi.org/10.1001/archinte.160.16.2498Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine. 2016;374(13):1221–31. doi: https://doi.org/10.1056/NEJMoa1505241Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine. 2016;374(13):1221–31. doi: https://doi.org/10.1056/NEJMoa1505241Chen IJ, Stanczyk FZ, Sriprasert I, Karim R, Shoupe D, Kono N, et al. Sex steroid hormones and subclinical atherosclerosis progression in postmenopausal women. European Journal of Endocrinology. 2025;192(3):248–56. doi: https://doi.org/10.1093/ejendo/lvaf032Chen IJ, Stanczyk FZ, Sriprasert I, Karim R, Shoupe D, Kono N, et al. Sex steroid hormones and subclinical atherosclerosis progression in postmenopausal women. European Journal of Endocrinology. 2025;192(3):248–56. doi: https://doi.org/10.1093/ejendo/lvaf032Anagnostis P, Mikhailidis DP, Blinc A, Jensterle M, Ježovnik MK, Schernthaner G-H, et al. The Effect of Menopause and Menopausal Hormone Therapy on the Riskof Peripheral Artery Disease. Current Vascular Pharmacology. 2023;21(5):293–6. doi: https://doi.org/10.2174/0115701611263345230919122907Anagnostis P, Mikhailidis DP, Blinc A, Jensterle M, Ježovnik MK, Schernthaner G-H, et al. The Effect of Menopause and Menopausal Hormone Therapy on the Riskof Peripheral Artery Disease. Current Vascular Pharmacology. 2023;21(5):293–6. doi: https://doi.org/10.2174/0115701611263345230919122907Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 2002;288(1):49–57. doi: https://doi.org/10.1001/jama.288.1.49Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 2002;288(1):49–57. doi: https://doi.org/10.1001/jama.288.1.49Davies RSM, Vohra RK, Bradbury AW, Adam DJ. The Impact of Hormone Replacement Therapy on the Pathophysiology of Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery. 2007;34(5):569–75. doi: https://doi.org/10.1016/j.ejvs.2007.06.002Davies RSM, Vohra RK, Bradbury AW, Adam DJ. The Impact of Hormone Replacement Therapy on the Pathophysiology of Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery. 2007;34(5):569–75. doi: https://doi.org/10.1016/j.ejvs.2007.06.002Поляков Д.C., Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Артемьева Е.Г. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА–ХСН. // Кардиология. — 2021. — Т.61. — №4. — С.4-14. [Polyakov DS, Fomin IV, Belenkov YuN, Mareev VYu, Ageev FT, Artemjeva EG, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of followup? Results of the EPOCHCHF study. Kardiologiia. 2021;61(4):4–14 (In Russ.)] doi: https://doi.org/10.18087/cardio.2021.4.n1628Polyakov DS, Fomin IV, Belenkov YuN, Mareev VYu, Ageev FT, Artemjeva EG, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of followup? Results of the EPOCHCHF study. Kardiologiia. 2021;61(4):4–14 (In Russ.) doi: https://doi.org/10.18087/cardio.2021.4.n1628Appiah D, Schreiner PJ, Demerath EW, Loehr LR, Chang PP, Folsom AR. Association of Age at Menopause With Incident Heart Failure: A Prospective Cohort Study and Meta‐Analysis. Journal of the American Heart Association. 2016;5(8):e003769. doi: https://doi.org/10.1161/JAHA.116.003769Appiah D, Schreiner PJ, Demerath EW, Loehr LR, Chang PP, Folsom AR. Association of Age at Menopause With Incident Heart Failure: A Prospective Cohort Study and Meta‐Analysis. Journal of the American Heart Association. 2016;5(8):e003769. doi: https://doi.org/10.1161/JAHA.116.003769Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. doi: https://doi.org/10.1136/bmj.e6409Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. doi: https://doi.org/10.1136/bmj.e6409Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, Khan S, Adams K, Goldman S, et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. Journal of the American College of Cardiology. 2003;42(7):1238–45. doi: https://doi.org/10.1016/S0735-1097(03)00938-0Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, Khan S, Adams K, Goldman S, et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. Journal of the American College of Cardiology. 2003;42(7):1238–45. doi: https://doi.org/10.1016/S0735-1097(03)00938-0Liu L, Klein L, Eaton C, Panjrath G, Martin LW, Chae CU, et al. Menopausal Hormone Therapy and Risks of First Hospitalized Heart Failure and its Subtypes During the Intervention and Extended Postintervention Follow-up of the Women’s Health Initiative Randomized Trials. Journal of Cardiac Failure. 2020;26(1):2–12. doi: https://doi.org/10.1016/j.cardfail.2019.09.006Liu L, Klein L, Eaton C, Panjrath G, Martin LW, Chae CU, et al. Menopausal Hormone Therapy and Risks of First Hospitalized Heart Failure and its Subtypes During the Intervention and Extended Postintervention Follow-up of the Women’s Health Initiative Randomized Trials. Journal of Cardiac Failure. 2020;26(1):2–12. doi: https://doi.org/10.1016/j.cardfail.2019.09.006Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women’s health outcomes by types, routes, and doses. Menopause. 2024;31(5):363–71. doi: https://doi.org/10.1097/GME.0000000000002335Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women’s health outcomes by types, routes, and doses. Menopause. 2024;31(5):363–71. doi: https://doi.org/10.1097/GME.0000000000002335Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillationdeveloped in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. doi: https://doi.org/10.1093/eurheartj/ehw210Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillationdeveloped in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. doi: https://doi.org/10.1093/eurheartj/ehw210Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. Circulation. 2005;112(12):1687–91. doi: https://doi.org/10.1161/CIRCULATIONAHA.105.553438Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. Circulation. 2005;112(12):1687–91. doi: https://doi.org/10.1161/CIRCULATIONAHA.105.553438Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(36):3314–414. doi: https://doi.org/10.1093/eurheartj/ehae176Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(36):3314–414. doi: https://doi.org/10.1093/eurheartj/ehae176Antoun I, Layton GR, Abdelrazik A, Eldesouky M, Zakkar M, Somani R, et al. The Pathophysiology of Sex Differences in Stroke Risk and Prevention in Atrial Fibrillation: A Comprehensive Review. Medicina. 2025;61(4):649. doi: https://doi.org/10.3390/medicina61040649Antoun I, Layton GR, Abdelrazik A, Eldesouky M, Zakkar M, Somani R, et al. The Pathophysiology of Sex Differences in Stroke Risk and Prevention in Atrial Fibrillation: A Comprehensive Review. Medicina. 2025;61(4):649. doi: https://doi.org/10.3390/medicina61040649Perez MV, Wang PJ, Larson JC, Virnig BA, Cochrane B, Curb JD, et al. Effects of Postmenopausal Hormone Therapy on Incident Atrial Fibrillation: The Women’s Health Initiative Randomized Controlled Trials. Circulation: Arrhythmia and Electrophysiology. 2012;5(6):1108–16. doi: https://doi.org/10.1161/CIRCEP.112.972224Perez MV, Wang PJ, Larson JC, Virnig BA, Cochrane B, Curb JD, et al. Effects of Postmenopausal Hormone Therapy on Incident Atrial Fibrillation: The Women’s Health Initiative Randomized Controlled Trials. Circulation: Arrhythmia and Electrophysiology. 2012;5(6):1108–16. doi: https://doi.org/10.1161/CIRCEP.112.972224Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njolstad I, et al. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588–97. doi: https://doi.org/10.1161/CIRCULATIONAHA.117.028981Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njolstad I, et al. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588–97. doi: https://doi.org/10.1161/CIRCULATIONAHA.117.028981Tsai W-C, Haung Y-B, Kuo H-F, Tang W-H, Hsu P-C, Su H-M, et al. Hormone replacement therapy and risk of atrial fibrillation in Taiwanese menopause women: A nationwide cohort study. Scientific Reports. 2016;6(1):24132. doi: https://doi.org/10.1038/srep24132Tsai W-C, Haung Y-B, Kuo H-F, Tang W-H, Hsu P-C, Su H-M, et al. Hormone replacement therapy and risk of atrial fibrillation in Taiwanese menopause women: A nationwide cohort study. Scientific Reports. 2016;6(1):24132. doi: https://doi.org/10.1038/srep24132Wong JA, Rexrode KM, Sandhu RK, Moorthy MV, Conen D, Albert CM. Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. Heart. 2017;103(24):1954–61. doi: https://doi.org/10.1136/heartjnl-2016-311002Wong JA, Rexrode KM, Sandhu RK, Moorthy MV, Conen D, Albert CM. Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. Heart. 2017;103(24):1954–61. doi: https://doi.org/10.1136/heartjnl-2016-311002Lee J, Kim Y, Park H, Kim C, Cho S, Kim J. Clinical Impact of Hormone Replacement Therapy on Atrial Fibrillation in Postmenopausal Women: A Nationwide Cohort Study. Journal of Clinical Medicine. 2021;10(23):5497. doi: https://doi.org/10.3390/jcm10235497Lee J, Kim Y, Park H, Kim C, Cho S, Kim J. Clinical Impact of Hormone Replacement Therapy on Atrial Fibrillation in Postmenopausal Women: A Nationwide Cohort Study. Journal of Clinical Medicine. 2021;10(23):5497. doi: https://doi.org/10.3390/jcm10235497Fleury M-A, Clavel M-A. Sex and Race Differences in the Pathophysiology, Diagnosis, Treatment, and Outcomes of Valvular Heart Diseases. Canadian Journal of Cardiology. 2021;37(7):980–91. doi: https://doi.org/10.1016/j.cjca.2021.02.003Fleury M-A, Clavel M-A. Sex and Race Differences in the Pathophysiology, Diagnosis, Treatment, and Outcomes of Valvular Heart Diseases. Canadian Journal of Cardiology. 2021;37(7):980–91. doi: https://doi.org/10.1016/j.cjca.2021.02.003Rodriguez-Arias JJ, Garcia-Alvarez A. Sex Differences in Pulmonary Hypertension. Frontiers in Aging. 2021;2:727558. doi: https://doi.org/10.3389/fragi.2021.727558Rodriguez-Arias JJ, Garcia-Alvarez A. Sex Differences in Pulmonary Hypertension. Frontiers in Aging. 2021;2:727558. doi: https://doi.org/10.3389/fragi.2021.727558Hye T, Dwivedi P, Li W, Lahm T, Nozik-Grayck E, Stenmark KR, et al. Newer insights into the pathobiological and pharmacological basis of the sex disparity in patients with pulmonary arterial hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2021;320(6):L1025–37. doi: https://doi.org/10.1152/ajplung.00559.2020Hye T, Dwivedi P, Li W, Lahm T, Nozik-Grayck E, Stenmark KR, et al. Newer insights into the pathobiological and pharmacological basis of the sex disparity in patients with pulmonary arterial hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2021;320(6):L1025–37. doi: https://doi.org/10.1152/ajplung.00559.2020Liu A, Schreier D, Tian L, Eickhoff JC, Wang Z, Hacker TA, et al. Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension. American Journal of Physiology-Heart and Circulatory Physiology. 2014;307(3):H273–83. doi: https://doi.org/10.1152/ajpheart.00758.2013Liu A, Schreier D, Tian L, Eickhoff JC, Wang Z, Hacker TA, et al. Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension. American Journal of Physiology-Heart and Circulatory Physiology. 2014;307(3):H273–83. doi: https://doi.org/10.1152/ajpheart.00758.2013Badlam JB, Badesch D, Brittain E, Cordell S, Ding T, Fox K, et al. Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a case–control study. Pulmonary Circulation. 2020;10(1):1–9. doi: https://doi.org/10.1177/2045894020908786Badlam JB, Badesch D, Brittain E, Cordell S, Ding T, Fox K, et al. Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a case–control study. Pulmonary Circulation. 2020;10(1):1–9. doi: https://doi.org/10.1177/2045894020908786Министерство здравоохранения Российской Федерации. Клинические рекомендации. Мигрень. 2024. Доступно на: https://cr.minzdrav.gov.ru/preview-cr/295_4Ministry of Health of Russian Federation. Clinical recommendations. Migraine. 2024. Av. at: https://cr.minzdrav.gov.ru/preview-cr/295_4]Nappi R, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C. Role of Estrogens in Menstrual Migraine. Cells. 2022;11(8):1355. doi: https://doi.org/10.3390/cells11081355Nappi R, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C. Role of Estrogens in Menstrual Migraine. Cells. 2022;11(8):1355. doi: https://doi.org/10.3390/cells11081355Academic Committee of the Korean Society of Menopause, Lee SR, Cho MK, Cho YJ, Chun S, Hong S-H, et al. The 2020 Menopausal Hormone Therapy Guidelines. Journal of Menopausal Medicine. 2020;26(2):69–98. doi: https://doi.org/10.6118/jmm.20000Academic Committee of the Korean Society of Menopause, Lee SR, Cho MK, Cho YJ, Chun S, Hong S-H, et al. The 2020 Menopausal Hormone Therapy Guidelines. Journal of Menopausal Medicine. 2020;26(2):69–98. doi: https://doi.org/10.6118/jmm.20000Australasian Menopause Society. Migraine headaches, menopause and MHT/HRT. Available at: https://menopause.org.au/hp/information-sheets/migraine-headaches-menopause-and-mht-hrtAustralasian Menopause Society. Migraine headaches, menopause and MHT/HRT. Available at: https://menopause.org.au/hp/information-sheets/migraine-headaches-menopause-and-mht-hrtBritish Menopause Society. Migraine and HRT. Av. at: https://thebms.org.uk/publications/tools-for-clinicians/migraine-and-hrt/British Menopause Society. Migraine and HRT. Av. at: https://thebms.org.uk/publications/tools-for-clinicians/migraine-and-hrt/Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. Endocrine Practice. 2014;20(9):977–89. doi: https://doi.org/10.4158/EP14280.PSGarvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. Endocrine Practice. 2014;20(9):977–89. doi: https://doi.org/10.4158/EP14280.PS

The authors declare that there are no conflicts of interest present.